Combining Understanding of Immunological Mechanisms and Genetic Variants Toward Development of Personalized Medicine for Psoriasis Patients

Conclusion Although GWAS contributed insight into the utility of the genotype biomarker to treatment selection, adequately powered prospective studies will be required before clinical application of pharmacogenomics can become a reality. Genotype and phenotype assessment should be facilitated by the availability of detailed molecular analyses and data integration. Careful assessment of prospective GWAS data is essential to integrate findings into the clinical decision-making process, and thereby optimizing the treatment of patients with psoriasis in the future. Author Contributions BY, NG, and WY performed the project. CC provided vital guidance and insight to the work. WY and CC conceptualized the project. Funding This work was supported by the Ministry of Education (MOE) Fundamental Research Grant Scheme (FRGS/1/2015/SKK08/ TAYLOR/03/2) awarded to CC; Taylor’s Research Grant Scheme Major Grant (TRGS/MFS/1/2015/SBS/013) awarded to WY. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Footnote ^www.psort.org.uk References Aggarwal, S., Ghilardi, N., Xie, M. H., De Sauvage, F. J., and Gurney, A. L. (2003). Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910–1914. PubMed Abstract | Google Scholar Amatya, ...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research